BofA initiated coverage of Ryan Specialty with a Buy rating and $67 price target. The stock has traded at a premium to the insurance brokers given Ryan’s double-digit organic growth profile and leading position in the “rapidly expanding” excess and surplus market, the analyst tells investors in a research note. The firm thinks the company’s above-average growth profile is more sustainable than the stock’s current valuation implies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYAN:
- Ryan Specialty downgraded to Peer Perform from Outperform at Wolfe Research
- Ryan Specialty Group on the Brink: Unregistered Securities Sale Could Spell Legal Trouble and Investor Woes
- Ryan Specialty Group backs FY organic revenue growth rate 12.5%-14%
- Ryan Specialty Group updates ACCELERATE 2025 restructuring program
- Ryan Specialty Group reports Q1 adjusted EPS 35c, consensus 35c